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1. INTRODUCTION {#cam42916-sec-0005}
===============

Kidney cancer originates from the renal tubules and pelvis. Approximately 90% of kidney cancers are renal cell carcinomas, accounting for 2%‐3% of all adult malignancies.[1](#cam42916-bib-0001){ref-type="ref"} There are significant regional differences in the incidence of kidney cancer, with the highest incidence being observed in Northern America, New Zealand, Europe, and Australia and the lowest incidence being observed in Africa and the Pacific Islands.[2](#cam42916-bib-0002){ref-type="ref"} The incidence of kidney cancer is higher in males than in females, with the radio of 1.65:1, and the risk may be linked to smoking and obesity.[3](#cam42916-bib-0003){ref-type="ref"}, [4](#cam42916-bib-0004){ref-type="ref"} In 2016, an estimated 62 700 people in the United States were diagnosed with kidney cancer and 14 240 of whom died.[5](#cam42916-bib-0005){ref-type="ref"} Kidney cancer is an important disease threatening human health.

Currently, the prognosis of kidney cancer depends mainly on the pathological grade or tumor stage. The American Joint Committee on Cancer (AJCC) staging system has been widely used to predict the survival of kidney cancer patients based on the extent of tumor invasion (T), regional lymph node (N), and distant metastasis (M).[6](#cam42916-bib-0006){ref-type="ref"} Several other scoring systems, such as the Arterial Based Complexity Scoring System, nephrometry scoring systems, and Zonal NePhRO scoring system, had been proposed to standardize the evaluation of kidney cancer.[7](#cam42916-bib-0007){ref-type="ref"}, [8](#cam42916-bib-0008){ref-type="ref"}, [9](#cam42916-bib-0009){ref-type="ref"} However, these prognostic systems do not fully assess clinicopathological factors, such as age, gender, pathological grade, and marital status, which may reduce their prognostic effectiveness.

Nomogram, statistics‐based tool aggregating several independent risk factors into an intuitive graph, has been widely used in recent years to assess the prognosis for many types of cancer.[10](#cam42916-bib-0010){ref-type="ref"}, [11](#cam42916-bib-0011){ref-type="ref"}, [12](#cam42916-bib-0012){ref-type="ref"} Therefore, this study aimed to develop effective prognostic nomograms and a new scoring system based on a large data set to predict overall survival (OS) and cancer‐specific survival (CSS) of patients with kidney cancer to help clinicians provide personalized treatment recommendations.

2. MATERIALS AND METHODS {#cam42916-sec-0006}
========================

2.1. Data acquisition {#cam42916-sec-0007}
---------------------

Patients\' data in this study were obtained from Surveillance, Epidemiology, and End Results (SEER) database (SEER 21 Regs Limited‐Field Research Data and Hurricane Katrina Impacted Louisiana Cases, released April 2019, based on the November 2018 submission, vision 8.3.5). The SEER database covers approximately 28% of cancer registries in the United States.[13](#cam42916-bib-0013){ref-type="ref"} The clinical information of cancer patients provided by SEER database greatly facilitates clinical research.

2.2. Study population {#cam42916-sec-0008}
---------------------

Patients diagnosed with kidney cancer between 2005 and 2015 from the SEER database were selected for this study. All data on kidney cancer patients were collected from hospitals, and no patient had a history of another cancer. Patients without confirmed pathological results were excluded. Available patient information, including age, gender, race, marital status, pathological grade, surgery, T (extent of tumor invasion) stage, N (regional lymph node) stage, and M (distant metastasis) stage was collected. We excluded patients in which the information mentioned above was missing.

2.3. Statistical analysis {#cam42916-sec-0009}
-------------------------

We used patients diagnosed with kidney cancer between 2005 and 2011 as the primary cohort to establish nomograms. Univariate and multivariate Cox analyses were used to determine the independent prognostic factors. In the univariate Cox proportional hazard model, variables with *P* \< .05 were further analyzed in the multivariate Cox proportional hazard model. Significant prognostic factors were used to establish nomograms to predict the 1‐, 3‐, and 5‐year OS and CSS rates, and the ability for survival prediction of the factors was tested by receiver operating characteristic (ROC) curve. Internal and external validations were used to evaluate the prognostic accuracy of the nomograms. We used calibration curve and concordance index (C‐index) to internal and external evaluate the predictive accuracy of the nomograms (bootstraps with 1000 resample).

Patients diagnosed between 2012 and 2015 were used as the validation cohort for external validation. Because the data sets were completed in December 2017, patients diagnosed in 2012‐2013 and in 2014‐2015 were used for the external validation of 3‐ and 1‐year survival, respectively. C‐index and area under the curve (AUC) values of 100% represent perfect predictions. Generally, the C‐index values greater than 0.7 indicate that the nomogram has a good predictive ability.[14](#cam42916-bib-0014){ref-type="ref"} In the calibration curves, the closer the prediction curve is to the observation curve, the more accurate the prognostic prediction is.

In the univariate and multivariate Cox analyses, some variables indicated no significant association with OS or CSS and thus were not included in our nomogram. To analyze the effect of these variables on survival in patients with kidney cancer, we reduced the subgroup classification to decrease distribution differences in patients diagnosed with kidney cancer between 2005 and 2015. We also used propensity score matching (PSM) to balance the clinical information and reduce statistical bias. The variables race, age, gender, marital status, grade, T stage, N stage, M stage, and surgery were matched. Cox proportional hazard models and Kaplan‐Meier curves were used for survival comparison. We further developed a new prognostic scoring system for OS and CSS in patients with kidney cancer based on the hazard ratios (HRs) of each subgroup. The new prognostic scoring system showed a total of 80 points, with 0\~10 points indicating a good prognosis (stage I), 11\~25 points indicating a moderate prognosis (stage II), 26\~40 points indicating a poor prognosis (stage III), and 41\~80 points indicating a terrible prognosis (stage IV). Kaplan‐Meier curves were used to compare the OS and CSS of patients in different stages with the new scoring system and with the AJCC staging system. All statistical analyses were performed by R software, and two‐tailed *P* \< .05 were defined as statistical significance.

3. RESULTS {#cam42916-sec-0010}
==========

3.1. Baseline characteristics {#cam42916-sec-0011}
-----------------------------

A total of 70 481 patients diagnosed with kidney cancer between 2005 and 2015 were screened from the SEER database. Patients diagnosed between 2005 and 2011 (n = 42 890), as the primary cohort, were used to establish the nomograms. Patients diagnosed between 2012 and 2013 (n = 13 094) and between 2014 and 2015 (n = 14 497) were used for the external validation of 3‐ and 1‐year survival, respectively. The baseline characteristics of patients included in this study are listed in Table [1](#cam42916-tbl-0001){ref-type="table"}.

###### 

Baseline characteristics of kidney cancer patients from SEER database (n = 70 481, 2005‐2015)

  Patient characteristics              Primary cohort (n = 42 890, 2005‐2011)   Validation cohort 1 (n = 13 094, 2012‐2013)   Validation cohort 2 (n = 14 497, 2014‐2015)
  ------------------------------------ ---------------------------------------- --------------------------------------------- ---------------------------------------------
  Race                                                                                                                        
  White                                35 624 (83.1)                            10 718 (81.9)                                 11 810 (81.5)
  Black                                4721 (11.0)                              1486 (11.3)                                   1644 (11.3)
  Other                                2545 (5.9)                               890 (6.8)                                     1043 (7.2)
  Age                                                                                                                         
  \<50                                 8669 (20.2)                              2544 (19.4)                                   2766 (19.1)
  50‐59                                11 705 (27.3)                            3551 (27.1)                                   3868 (26.7)
  59‐69                                12 336 (28.8)                            4041 (30.9)                                   4585 (31.6)
  69‐79                                7624 (17.8)                              2301 (17.6)                                   2566 (17.7)
  ≥80                                  2556 (5.9)                               657 (5.0)                                     712 (4.9)
  Gender                                                                                                                      
  Male                                 27 079 (63.1)                            8329 (63.6)                                   9225 (63.6)
  Female                               15 811 (36.9)                            4765 (36.4)                                   5272 (36.4)
  Marital status                                                                                                              
  Married                              28 241 (65.8)                            8419 (64.3)                                   9255 (63.8)
  Divorced                             4110 (9.6)                               1276 (9.7)                                    1421 (9.8)
  Separated                            471 (1.1)                                180 (1.4)                                     182 (1.3)
  Widowed                              3664 (8.6)                               967 (7.4)                                     1025 (7.1)
  Single                               6404 (14.9)                              2252 (17.2)                                   2614 (18.0)
  Grade                                                                                                                       
  Well                                 5764 (13.5)                              1479 (11.3)                                   1548 (10.7)
  Moderately                           21 887 (51.0)                            6708 (51.2)                                   7249 (50.0)
  Poor                                 12 114 (28.2)                            3864 (29.5)                                   4413 (30.4)
  Undifferentiated                     3125 (7.3)                               1043 (8.0)                                    1287 (8.9)
  T (tumor invasion)                                                                                                          
  T1a                                  18 316 (42.7)                            5779 (44.1)                                   6418 (44.3)
  T1b                                  9972 (23.3)                              2985 (22.8)                                   3321 (22.9)
  T2                                   5292 (12.3)                              1480 (11.3)                                   1508 (10.4)
  T3a                                  4461 (10.4)                              1387 (10.6)                                   1491 (10.3)
  T3b                                  3991 (9.3)                               1253 (9.6)                                    1510 (10.4)
  T3c                                  168 (0.4)                                46 (0.4)                                      62 (0.4)
  T4                                   690 (1.6)                                164 (1.2)                                     187 (1.3)
  N (regional lymph node)                                                                                                     
  No                                   41 106 (95.8)                            12 501 (95.5)                                 13 915 (96.0)
  Yes                                  1784 (4.2)                               593 (4.5)                                     582 (4.0)
  M (metastasis)                                                                                                              
  No                                   39 543 (92.2)                            12 096 (92.4)                                 13 393 (92.4)
  Yes                                  3347 (7.8)                               998 (7.6)                                     1104 (7.6)
  Surgery                                                                                                                     
  No                                   930 (2.2)                                365 (2.8)                                     448 (3.1)
  Yes                                  41 960 (97.8)                            12 769 (97.2)                                 14 049 (96.9)
  Pathology                                                                                                                   
  Clear cell adenocarcinoma            26 012 (60.7)                            8701 (66.5)                                   10 010 (69.0)
  Adenocarcinoma with mixed subtypes   1042 (2.4)                               340 (2.6)                                     419 (2.9)
  Papillary adenocarcinoma             4745 (11.1)                              1577 (12.0)                                   1738 (12.0)
  Chromophobe cell carcinoma           1949 (4.5)                               593 (4.5)                                     563 (3.9)
  Other                                1808 (4.2)                               419 (3.2)                                     405 (2.8)
  Unknown                              7334 (17.1)                              1464 (11.2)                                   1362 (9.4)

The primary cohort was used to establish nomograms. The validation cohort 1 and validation cohort 2 were used for the external validation of 3‐ and 1‐y survival of nomograms, respectively.
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3.2. Independent prognostic factors {#cam42916-sec-0012}
-----------------------------------

The results of the univariate and multivariate Cox analyses of OS and CSS of the primary cohort are listed in Tables [2](#cam42916-tbl-0002){ref-type="table"} and [3](#cam42916-tbl-0003){ref-type="table"}, respectively. According to the univariate cox analysis, the variables age, gender, marital status, grade, T stage, M stage, and surgery were significantly associated with OS and CSS. These significant variables were further entered into the multivariate Cox analysis, all of which were considered independent prognostic factors for OS and CSS (Tables [2](#cam42916-tbl-0002){ref-type="table"} and [3](#cam42916-tbl-0003){ref-type="table"}). In the multivariate Cox analyses, with regard to OS, older age (compared with \<60 years old, ≥80 years old: HR = 4.82; 95% CI = 4.47‐5.19; *P* \< .001) and M1 classification (compared with M0: HR = 4.34; 95% CI = 4.12‐4.56; *P* \< .001) were associated with the highest risk of death (Table [2](#cam42916-tbl-0002){ref-type="table"}). With regard to CSS, higher T stage (compared with T1a, T1b‐T4: HR = 2.30‐9.62; *P* \< .001 for all) and M1 classification (compared with M0: HR = 5.44; 95% CI = 5.14‐5.76; *P* \< .001) were related to the highest risk of death (Table [3](#cam42916-tbl-0003){ref-type="table"}).

###### 

Univariate and multivariate Cox analyses for overall survival in the primary cohort (n = 42 890, 2005‐2011)

+-------------------------+---------------------+-----------------------+--------+
| Patient characteristics | Univariate analysis | Multivariate analysis |        |
|                         |                     |                       |        |
|                         | *P* value           |                       |        |
+=========================+=====================+=======================+========+
| Age                     | \<.001              |                       | \<.001 |
+-------------------------+---------------------+-----------------------+--------+
| \<50                    | Reference           |                       |        |
+-------------------------+---------------------+-----------------------+--------+
| 50‐59                   | 1.40 (1.31‐1.49)    | \<.001                |        |
+-------------------------+---------------------+-----------------------+--------+
| 59‐69                   | 1.95 (1.84‐2.08)    | \<.001                |        |
+-------------------------+---------------------+-----------------------+--------+
| 69‐79                   | 3.02 (2.83‐3.21)    | \<.001                |        |
+-------------------------+---------------------+-----------------------+--------+
| ≥80                     | 4.82 (4.47‐5.19)    | \<.001                |        |
+-------------------------+---------------------+-----------------------+--------+
| Gender                  | \<.001              |                       | \<.001 |
+-------------------------+---------------------+-----------------------+--------+
| Male                    | Reference           |                       |        |
+-------------------------+---------------------+-----------------------+--------+
| Female                  | 0.80 (0.77‐0.84)    | \<.001                |        |
+-------------------------+---------------------+-----------------------+--------+
| Marital status          | \<.001              |                       | \<.001 |
+-------------------------+---------------------+-----------------------+--------+
| Married                 | Reference           |                       |        |
+-------------------------+---------------------+-----------------------+--------+
| Divorced                | 1.37 (1.29‐1.45)    | \<.001                |        |
+-------------------------+---------------------+-----------------------+--------+
| Separated               | 1.55 (1.32‐1.81)    | \<.001                |        |
+-------------------------+---------------------+-----------------------+--------+
| Widowed                 | 1.43 (1.35‐1.51)    | \<.001                |        |
+-------------------------+---------------------+-----------------------+--------+
| Single                  | 1.37 (1.31‐1.45)    | \<.001                |        |
+-------------------------+---------------------+-----------------------+--------+
| Grade                   | \<.001              |                       | \<.001 |
+-------------------------+---------------------+-----------------------+--------+
| Well                    | Reference           |                       |        |
+-------------------------+---------------------+-----------------------+--------+
| Moderately              | 1.02 (0.96‐1.08)    | .545                  |        |
+-------------------------+---------------------+-----------------------+--------+
| Poor                    | 1.35 (1.27‐1.44)    | \<.001                |        |
+-------------------------+---------------------+-----------------------+--------+
| Undifferentiated        | 2.34 (2.17‐2.52)    | \<.001                |        |
+-------------------------+---------------------+-----------------------+--------+
| T stage                 | \<.001              |                       | \<.001 |
+-------------------------+---------------------+-----------------------+--------+
| T1a                     | Reference           |                       |        |
+-------------------------+---------------------+-----------------------+--------+
| T1b                     | 1.41 (1.35‐1.49)    | \<.001                |        |
+-------------------------+---------------------+-----------------------+--------+
| T2                      | 1.73 (1.63‐1.83)    | \<.001                |        |
+-------------------------+---------------------+-----------------------+--------+
| T3a                     | 2.21 (2.09‐2.34)    | \<.001                |        |
+-------------------------+---------------------+-----------------------+--------+
| T3b                     | 2.57 (2.42‐2.72)    | \<.001                |        |
+-------------------------+---------------------+-----------------------+--------+
| T3c                     | 3.76 (3.15‐4.94)    | \<.001                |        |
+-------------------------+---------------------+-----------------------+--------+
| T4                      | 3.99 (3.63‐4.39)    | \<.001                |        |
+-------------------------+---------------------+-----------------------+--------+
| M stage                 | \<.001              |                       | \<.001 |
+-------------------------+---------------------+-----------------------+--------+
| M0                      | Reference           |                       |        |
+-------------------------+---------------------+-----------------------+--------+
| M1                      | 4.34 (4.12‐4.56)    | \<.001                |        |
+-------------------------+---------------------+-----------------------+--------+
| Surgery                 | \<.001              |                       | \<.001 |
+-------------------------+---------------------+-----------------------+--------+
| Yes                     | Reference           |                       |        |
+-------------------------+---------------------+-----------------------+--------+
| No                      | 3.21 (2.97‐3.48)    | \<.001                |        |
+-------------------------+---------------------+-----------------------+--------+
| Race                    | .321                |                       |        |
+-------------------------+---------------------+-----------------------+--------+
| N stage                 | .887                |                       |        |
+-------------------------+---------------------+-----------------------+--------+
| Pathology               | .842                |                       |        |
+-------------------------+---------------------+-----------------------+--------+

Abbreviations: CI, confidence interval; HR, hazard ratio.
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###### 

Univariate and multivariate Cox analyses for cancer‐specific survival in the primary cohort (n = 42 890, 2005‐2011)

+-------------------------+---------------------+-----------------------+--------+
| Patient characteristics | Univariate analysis | Multivariate analysis |        |
|                         |                     |                       |        |
|                         | *P* value           |                       |        |
+=========================+=====================+=======================+========+
| Age                     | \<.001              |                       | \<.001 |
+-------------------------+---------------------+-----------------------+--------+
| \<50                    | Reference           |                       |        |
+-------------------------+---------------------+-----------------------+--------+
| 50‐59                   | 1.17 (1.08‐1.26)    | \<.001                |        |
+-------------------------+---------------------+-----------------------+--------+
| 59‐69                   | 1.44 (1.34‐1.55)    | \<.001                |        |
+-------------------------+---------------------+-----------------------+--------+
| 69‐79                   | 1.88 (1.73‐2.04)    | \<.001                |        |
+-------------------------+---------------------+-----------------------+--------+
| ≥80                     | 2.49 (2.25‐2.76)    | \<.001                |        |
+-------------------------+---------------------+-----------------------+--------+
| Gender                  | .001                |                       | \<.001 |
+-------------------------+---------------------+-----------------------+--------+
| Male                    | Reference           |                       |        |
+-------------------------+---------------------+-----------------------+--------+
| Female                  | 0.90 (0.86‐0.95)    | .001                  |        |
+-------------------------+---------------------+-----------------------+--------+
| Marital status          | \<.001              |                       | \<.001 |
+-------------------------+---------------------+-----------------------+--------+
| Married                 | Reference           |                       |        |
+-------------------------+---------------------+-----------------------+--------+
| Divorced                | 1.19 (1.10‐1.28)    | \<.001                |        |
+-------------------------+---------------------+-----------------------+--------+
| Separated               | 1.42 (1.16‐1.75)    | \<.001                |        |
+-------------------------+---------------------+-----------------------+--------+
| Widowed                 | 1.22 (1.13‐1.33)    | \<.001                |        |
+-------------------------+---------------------+-----------------------+--------+
| Single                  | 1.19 (1.11‐1.27)    | \<.001                |        |
+-------------------------+---------------------+-----------------------+--------+
| Grade                   | \<.001              |                       | \<.001 |
+-------------------------+---------------------+-----------------------+--------+
| Well                    | Reference           |                       |        |
+-------------------------+---------------------+-----------------------+--------+
| Moderately              | 1.10(0.99‐1.22)     | .078                  |        |
+-------------------------+---------------------+-----------------------+--------+
| Poor                    | 1.97 (1.77‐2.18)    | \<.001                |        |
+-------------------------+---------------------+-----------------------+--------+
| Undifferentiated        | 3.51 (3.14‐3.92)    | \<.001                |        |
+-------------------------+---------------------+-----------------------+--------+
| T stage                 | \<.001              |                       | \<.001 |
+-------------------------+---------------------+-----------------------+--------+
| T1a                     | Reference           |                       |        |
+-------------------------+---------------------+-----------------------+--------+
| T1                      | 2.30 (2.11‐2.52)    | \<.001                |        |
+-------------------------+---------------------+-----------------------+--------+
| T2                      | 3.93 (3.60‐4.29)    | \<.001                |        |
+-------------------------+---------------------+-----------------------+--------+
| T3a                     | 5.22 (4.78‐5.70)    | \<.001                |        |
+-------------------------+---------------------+-----------------------+--------+
| T3b                     | 6.28 (5.75‐6.85)    | \<.001                |        |
+-------------------------+---------------------+-----------------------+--------+
| T3c                     | 9.10 (8.08‐10.24)   | \<.001                |        |
+-------------------------+---------------------+-----------------------+--------+
| T4                      | 9.62 (7.90‐11.72)   | \<.001                |        |
+-------------------------+---------------------+-----------------------+--------+
| M stage                 | \<.001              |                       | \<.001 |
+-------------------------+---------------------+-----------------------+--------+
| M0                      | Reference           |                       |        |
+-------------------------+---------------------+-----------------------+--------+
| M1                      | 5.44 (5.14‐5.76)    | \<.001                |        |
+-------------------------+---------------------+-----------------------+--------+
| Surgery                 | \<.001              |                       | \<.001 |
+-------------------------+---------------------+-----------------------+--------+
| Yes                     | Reference           |                       |        |
+-------------------------+---------------------+-----------------------+--------+
| No                      | 3.83 (3.49‐4.20)    | \<.001                |        |
+-------------------------+---------------------+-----------------------+--------+
| Race                    | .120                |                       |        |
+-------------------------+---------------------+-----------------------+--------+
| N stage                 | .801                |                       |        |
+-------------------------+---------------------+-----------------------+--------+
| Pathology               | .350                |                       |        |
+-------------------------+---------------------+-----------------------+--------+

Abbreviations: CI, confidence interval; HR, hazard ratio.
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3.3. Establishment and validation of the prognostic nomograms {#cam42916-sec-0013}
-------------------------------------------------------------

The independent prognostic factors were used to establish nomograms to predict the 1‐, 3‐, and 5‐year OS and CSS rates of kidney cancer patients (Figure [1](#cam42916-fig-0001){ref-type="fig"}). The predictive ability for 1‐, 3‐, and 5‐year OS and CSS of kidney cancer patients using variables from our developed nomograms was tested by ROC curves. The favorable 1‐, 3‐, and 5‐year AUC values (for OS, AUC = 0.858, 0.829, and 0.812, respectively; and for CSS, AUC = 0.921, 0.905, and 0.890, respectively) indicated good ability for survival prediction of variables in kidney cancer patients (Figure [2](#cam42916-fig-0002){ref-type="fig"}). The accuracy of nomograms was evaluated internally with C‐index values and correction curve. The favorable C‐index values (for OS, C‐index = 0.776, 95% CI = 0.772‐0.780; and for CSS, C‐index = 0.856, 95% CI = 0.852‐0.860) indicated that the proposed nomograms could accurately predict the 1‐, 3‐, and 5‐year OS and CSS of kidney cancer patients. On the other hand, the 1‐, 3‐, and 5‐year calibration curves of OS and CSS demonstrated good consistency between predicted survival and observed survival (Figure [3](#cam42916-fig-0003){ref-type="fig"}), which could also prove the validity of prognostic nomograms.

![Nomograms to predict the 1‐, 3‐, and 5‐y overall survival (OS) and cancer‐specific survival (CSS) rates of kidney cancer patients. A, 1‐, 3‐, and 5‐y OS rate; (B) 1‐, 3‐, and 5‐y CSS rate](CAM4-9-2710-g001){#cam42916-fig-0001}

![Receiver operating characteristic curve to test the predictive ability for 1‐, 3‐, and 5‐y overall survival (OS) and cancer‐specific survival (CSS) using variables from our developed nomograms in kidney cancer patients. Receiver operating characteristic curve for predicting (A) 1‐y OS; (B) 1‐y CSS; (C) 3‐y OS; (D) 3‐y CSS; (E) 5‐y OS; (F) 5‐y CSS](CAM4-9-2710-g002){#cam42916-fig-0002}

![The calibration curves to internal verify the nomograms in the primary data set. Calibration curves for predicting (A) 1‐y OS; (B) 1‐y CSS; (C) 3‐y OS; (D) 3‐y CSS; (E) 5‐y OS; (F) 5‐y CSS](CAM4-9-2710-g003){#cam42916-fig-0003}

We further used C‐index and calibration curve for the external verification of the nomograms. The excellent C‐index values (OS: 1‐year value = 0.841, 95% CI = 0.829‐0.853; 3‐year value = 0.814, 95% CI = 0.804‐0.824; CSS: 1‐year value = 0.904, 95% CI = 0.894‐0.914; 3‐year value = 0.894, 95% CI = 0.886‐0.902) and calibration curves indicated good agreements between prediction and actual observation (Figure [4](#cam42916-fig-0004){ref-type="fig"}). These internal and external validations indicate that the prognostic nomograms we proposed are effective and accurate in evaluating the 1‐, 3‐, and 5‐year OS and CSS of patients with kidney cancer.

![The calibration curves to external verify the nomograms in the validation data set. Calibration curves for predicting (A) 1‐y OS; (B) 1‐y CSS; (C) 3‐y OS; (D) 3‐y CSS](CAM4-9-2710-g004){#cam42916-fig-0004}

3.4. The effect of other variables on survival {#cam42916-sec-0014}
----------------------------------------------

We used univariate and multivariate Cox analyses to determine the independent prognostic factors, the variables N stage, race and pathology had no statistical significance in OS and CSS (*P* \> .05). To analyze the effects of the abovementioned variables on survival in kidney cancer patients, we reduced the subgroup classification to decrease distribution differences in patients diagnosed with kidney cancer between 2005 and 2015, and the baseline characteristics of the patients are listed in Table [4](#cam42916-tbl-0004){ref-type="table"}. We further used PSM to balance the clinical information and reduce the statistical bias and found kidney cancer patients with regional lymph node metastasis had a slightly increased risk of death compared to those without regional lymph node metastasis (overall death: HR = 1.09; 95% CI = 1.00‐1.17; *P* = .034; cancer‐specific death: HR = 1.13; 95% CI = 1.02‐1.25; *P* = .018), and black patients had the worst prognosis of all the races (Table [5](#cam42916-tbl-0005){ref-type="table"}). We generated Kaplan‐Meier curves to compare the OS and CSS of kidney cancer patients with and without regional lymph node metastasis (Figure [5](#cam42916-fig-0005){ref-type="fig"}). Regarding the pathological types, the *P* values were not significant, even after reducing differences between subgroups and matching clinical information (Table [5](#cam42916-tbl-0005){ref-type="table"}).

###### 

Baseline characteristics of kidney patients after reduced subgroup classification (n = 70 481, 2005‐2015)

  Patient characteristics   No. of patients (%)
  ------------------------- ---------------------
  Race                      
  White                     58 152 (82.5)
  Black                     7851 (11.1)
  Other                     4478 (6.4)
  Gender                    
  Male                      44 633 (63.3)
  Female                    25 848 (36.7)
  Age                       
  \<60                      33 103 (47.0)
  60‐80                     20 962 (29.7)
  \>80                      16 416 (23.3)
  Marital status            
  Married                   45 915 (65.1)
  Sep/Div/Wid               13 296 (18.9)
  Single                    11 270 (16.0)
  Surgery                   
  Yes                       68 738 (97.5)
  No                        1743 (2.5)
  Grade                     
  Well                      8791 (12.5)
  Moderately                35 844 (50.9)
  Poor                      20 391 (28.9)
  Undifferentiated          5455 (7.7)
  T (tumor invasion)        
  T1                        46 791 (66.4)
  T2                        8280 (11.7)
  T3                        14 369 (20.4)
  T4                        1041 (1.5)
  N (regional lymph node)   
  Yes                       2959 (4.2)
  No                        67 522 (95.8)
  M (metastasis)            
  Yes                       5449 (7.7)
  No                        65 032 (92.3)
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###### 

The comparison of overall death risk and all cancer‐specific death risk on survival of kidney cancer patients for variables not included in the nomograms

+-------------------------+------------------+-----------+------------------+-----------+
| Patient characteristics | Overall          | *P* value | Cancer‐specific  | *P* value |
|                         |                  |           |                  |           |
|                         | HR (95% CI)      |           | HR (95% CI)      |           |
+=========================+==================+===========+==================+===========+
| N (regional lymph node) |                  |           |                  |           |
+-------------------------+------------------+-----------+------------------+-----------+
| Yes vs None             | 1.09 (1.00‐1.17) | .034      | 1.13 (1.02‐1.25) | .018      |
+-------------------------+------------------+-----------+------------------+-----------+
| Race                    |                  |           |                  |           |
+-------------------------+------------------+-----------+------------------+-----------+
| Black vs White          | 1.28 (1.22‐1.35) | \<.001    | 1.27 (1.18‐1.36) | \<.001    |
+-------------------------+------------------+-----------+------------------+-----------+
| Other vs White          | 0.90 (0.85‐0.96) | .002      | 0.96 (0.89‐1.05) | .372      |
+-------------------------+------------------+-----------+------------------+-----------+
| Pathology               |                  |           |                  |           |
+-------------------------+------------------+-----------+------------------+-----------+
| B vs A                  | 1.08 (0.98‐1.20) | .127      | 1.13 (0.99‐1.30) | .060      |
+-------------------------+------------------+-----------+------------------+-----------+
| C vs A                  | 1.01 (0.96‐1.06) | .700      | 1.04 (0.97‐1.11) | .227      |
+-------------------------+------------------+-----------+------------------+-----------+
| D vs A                  | 1.01 (0.93‐1.09) | .819      | 1.06 (0.96‐1.18) | .252      |
+-------------------------+------------------+-----------+------------------+-----------+
| E vs A                  | 1.07 (0.98‐1.16) | .128      | 1.16 (1.03‐1.30) | .120      |
+-------------------------+------------------+-----------+------------------+-----------+
| F vs A                  | 1.00 (0.96‐1.05) | .988      | 1.02 (0.96‐1.08) | .534      |
+-------------------------+------------------+-----------+------------------+-----------+

The comparisons between groups were performed after propensity matching score adjusted.

Abbreviations: A, clear cell adenocarcinoma; B, adenocarcinoma with mixed subtypes; C, papillary adenocarcinoma; CI, confidence interval; D, chromophobe cell carcinoma; E, other types; F, unknown; HR, hazard ratio.
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![The comparison of overall survival and cancer‐specific survival between kidney cancer patients with and without regional lymph node metastasis. Kaplan‐Meier curves for comparison (A) overall survival; (B) cancer‐specific survival. PSM, propensity score matching](CAM4-9-2710-g005){#cam42916-fig-0005}

3.5. Establishment of Aggtrmmns prognostic scoring system {#cam42916-sec-0015}
---------------------------------------------------------

According to the HRs of the subgroups shown in Tables [2](#cam42916-tbl-0002){ref-type="table"}, [3](#cam42916-tbl-0003){ref-type="table"}, and [5](#cam42916-tbl-0005){ref-type="table"}, we established a new score system to evaluate OS and CSS of patients with kidney cancer. The prognostic score system was based on age, gender, race, marital status, grade, TNM stage, and surgery of kidney cancer patients. The scores of each subgroup are listed in Table [6](#cam42916-tbl-0006){ref-type="table"}. Based on the first letter of each of the above variables, we named this system the Aggtrmmns scoring system. We used Kaplan‐Meier curves to compare the OS and CSS of kidney cancer patients determined with the new scoring system to those determined with the AJCC staging system (Figure [6](#cam42916-fig-0006){ref-type="fig"}) and found that OS rates and CSS rates of kidney cancer patients with different stages were more explicit when our scoring system was used (Table [7](#cam42916-tbl-0007){ref-type="table"}).

###### 

The risk scores of Aggtrmmns prognostic scoring system for overall death and specific death of patients with kidney cancer

  Patient characteristics   All‐cause death points   Cancer‐specific death points
  ------------------------- ------------------------ ------------------------------
  Age                                                
  \<50                      0                        0
  50‐59                     2                        1
  59‐69                     5                        2
  69‐79                     11                       3
  ≥80                       20                       6
  Gender                                             
  Male                      1                        0
  Female                    0                        0
  Marital status                                     
  Married                   0                        0
  Divorced                  2                        1
  Separated                 3                        2
  Widowed                   2                        1
  Single                    2                        1
  Grade                                              
  Well                      0                        0
  Moderately                0                        0
  Poor                      2                        4
  Undifferentiated          7                        10
  Race                                               
  White                     1                        0
  Black                     2                        1
  Other                     0                        0
  T stage                                            
  T1a                       0                        0
  T1b                       2                        5
  T2                        4                        11
  T3a                       6                        16
  T3b                       8                        20
  T3c                       15                       31
  T4                        16                       33
  N stage                                            
  No                        0                        0
  Yes                       1                        0
  M stage                                            
  M0                        0                        0
  M1                        18                       17
  Surgery                                            
  No                        12                       11
  Yes                       0                        0

The Aggtrmmns prognostic scoring system with a total of 80 points, with 0\~10 points indicating a good prognosis (stage I), 11\~25 points indicating a moderate prognosis (stage II), 26\~40 points indicating a poor prognosis (stage III), and 40\~80 points indicating the tumor was deadly to survival (stage IV).
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![The comparison of overall survival (OS) and cancer‐specific survival (CSS) based on the stages of Aggtrmmns scoring system and AJCC staging system. Kaplan‐Meier curves for comparison OS in (A) AJCC and (B) Aggtrmmns staging system and CSS in (C) AJCC and (D) Aggtrmmns staging system.](CAM4-9-2710-g006){#cam42916-fig-0006}

###### 

The comparison of overall and cancer‐specific survival rates of kidney cancer patients between AJCC staging system and Aggtrmmns scoring system

  Stage       Survival time   AJCC staging system   Aggtrmmns scoring system                                   
  ----------- --------------- --------------------- -------------------------- ------ -------- ------ -------- ------
  Stage I     1‐y             44 046                93.9                       95.5   37 125   98.6   40 529   99.5
  3‐y         87.1            91.6                  95.6                       98.5                            
  5‐y         81.1            88.8                  92.3                       97.3                            
  Stage II    1‐y             7050                  94.4                       95.9   25 410   94.0   20 253   97.1
  3‐y         86.1            90.4                  83.8                       90.8                            
  5‐y         79.8            86.4                  74.1                       85.6                            
  Stage III   1‐y             13 542                90.7                       92.5   6098     70.0   6234     79.8
  3‐y         80.4            84.6                  44.7                       59.4                            
  5‐y         72.4            79.9                  31.0                       47.9                            
  Stage IV    6‐mo            5843                  91.7                       93.2   1848     50.1   3465     63.7
  1‐y         87.1            89.4                  33.5                       46.3                            
  3‐y         75.0            79.9                  13.6                       21.6                            
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4. DISCUSSION {#cam42916-sec-0016}
=============

Nomogram has become increasingly popular for its important role in personalized cancer prediction,[15](#cam42916-bib-0015){ref-type="ref"} which can help clinicians predict the survival of cancer patients with individual information. At present, the AJCC staging system and Fuhrman pathological grading system are widely used to evaluate the prognosis of kidney cancer patients, but the clinical information of patients cannot be individually and fully evaluated, which may limit the prediction effect. Therefore, this study aimed to establish prognostic nomograms to accurately and effectively predict the OS and CSS of patients with kidney cancer. As a result, nomograms for 1‐, 3‐, and 5‐year OS and CSS were established, and their accuracy was demonstrated by internal and external validations. The prognostic nomograms we proposed might promote the popularization of individualized treatment and survival assessment for kidney cancer patients.

The variables age, gender, marital status, grade, T stage, M stage, and surgery were included in our nomogram as independent prognostic factors. As shown in our nomogram, older patients with kidney cancer had worse OS and CSS, and the risk of death was more significant in CSS. In general, older patients have more chronic diseases and less resistance to disease, which may lead to a higher risk of overall death and cancer‐specific death. The effect of gender on kidney cancer patient survival was previously reported, as a group, kidney cancer in males presented with larger, higher stage, higher grade and faster progression than in females,[16](#cam42916-bib-0016){ref-type="ref"}, [17](#cam42916-bib-0017){ref-type="ref"} and females had a better chance of recovering renal function than males after radical nephrectomy.[18](#cam42916-bib-0018){ref-type="ref"} Marital status has been proven to be an independent prognostic factor and affects the survival of many types of cancer patients, such as prostate cancer, lung cancer, breast cancer, non‐Hodgkin lymphoma, and ovarian cancer.[19](#cam42916-bib-0019){ref-type="ref"} In these types of cancer, married patients have better OS and CSS than those with other marital conditions.[19](#cam42916-bib-0019){ref-type="ref"} A previous study on kidney cancer showed that married patients had the highest survival rate, followed by those who were divorced/ separated, and the widowed patients had the lowest survival rate.[20](#cam42916-bib-0020){ref-type="ref"} However, the above study did not analyze separated and divorced patients separately, nor did they use PSM to balance the clinical variables. In our study, separated patients with kidney cancer had the highest risk of death (compared with married, OS: HR = 1.55; 95% CI = 1.32‐1.81; CSS: HR = 1.42; 95% CI = 1.16‐1.75; *P* \< .001 for all). We further used PSM to balance the clinical variables and analyzed the impact of different marital status on the survival of kidney cancer patients. The variables race, age, gender, marital status, grade, T stage, N stage, M stage, pathology, and surgery were matched. We found separated status had the most adverse impact on OS (referent: married, HR: 1.73, 95% CI = 1.49‐2.01; *P* \< .001) and CSS (referent: married, HR: 1.71, 95% CI = 1.40‐2.01; *P* \< .001), and married patients had the best OS and CSS (Table [S1](#cam42916-sup-0001){ref-type="supplementary-material"}). The effects of gender and marital status on the OS and CSS of kidney cancer patients in our study were consistent with those from previous reports, which could confirm the authenticity of our nomogram on the other hand.

The variables N stage, race, and pathology had no statistical significance in the univariate Cox analysis and thus were not included in the nomograms. After reducing the subgroup classification to decrease distribution differences and using PSM to reduce statistical bias, we found kidney cancer patients with regional lymph node metastasis had a slightly increased risk of death compared to those without regional lymph node metastasis (HR = 1.09 for OS and HR = 1.13 for CSS; *P* \< .05 for all). Whether or not implement regional lymph node dissection after radical nephrectomy has been controversial. A prospective study by European Organization in 2008 reported that regional lymph node dissection after radical nephrectomy had no significant effect on survival or cancer recurrence.[21](#cam42916-bib-0021){ref-type="ref"} However, many thought that most patients in the trial had low‐stage tumors with a negligible risk of lymph node involvement.[22](#cam42916-bib-0022){ref-type="ref"} Recent views stated that lymph node dissection was not recommended for localized kidney cancer, and patients with stage T3‐T4, a high Fuhrman grade, sarcomatoid features, and/or coagulation tumor necrosis might benefit from regional lymph node dissection.[23](#cam42916-bib-0023){ref-type="ref"} However, due to the absence of information on surgical methods in the SEER database, we could not perform further statistical analysis. Psychotherapy is an important aspect of cancer treatment, and stress might accelerate the cancer process.[24](#cam42916-bib-0024){ref-type="ref"} Regional lymph node metastasis in many types of cancer has a significant impact on survival, which might make patients anxious and negatively affect their survival. Our study revealed that regional lymph node metastasis had a slight effect on survival in patients with kidney cancer, which could reduce panic of patients and improved the effect of treatment. In the analysis of kidney cancer patients for race, black patients had the worst survival, followed by white patients, and the survival of other race was the best. Our results are consistent with those from a previous study, showing that black patients with kidney cancer have a high incidence and a low survival rate, while the trend was reversed for Asians/Pacific Islanders.[25](#cam42916-bib-0025){ref-type="ref"}

The Aggtrmmns prognostic scoring system we proposed combined the clinicopathological information of kidney cancer patients with a total of 80 points, among which the TNM stage accounts for 35 points in OS and 50 points in CSS. Therefore, the Aggtrmmns prognostic scoring system could assess the OS and CSS of kidney cancer patients more efficiently than the AJCC staging system. Combined with the prognostic nomograms and Aggtrmmns scoring system, we could evaluate the OS and CSS of patients with kidney cancer more effectively and accurately, which might be helpful for clinicians in formulating treatment plans and adjusting follow‐up strategies. For example, in kidney cancer patients with poor prognosis, we could implement additional treatments and reduce follow‐up time to monitor the disease more effectively.

Our study still had some limitations. First, the treatment method used, such as radiation, chemotherapy, and immunotherapy, might have affected the survival of patients with kidney cancer, and the absence of treatment information in the SEER database might have introduced bias to our results. Second, renal function is an important factor affecting the survival of kidney cancer patients. If information on renal function or hemodialysis was added, our prognostic nomograms and scoring system would be more complete. Last, because our study was essentially retrospective and decreased statistical power in the subgroup analysis, larger and prospective studies are needed to prove our results.

5. CONCLUSIONS {#cam42916-sec-0017}
==============

With data from a large set, we developed prognostic nomograms and Aggtrmmns scoring system and demonstrated that those tools could make individual OS and CSS predictions for patients with kidney cancer. The proposed survival models of kidney cancer may help clinicians make individual therapies and adjust follow‐up strategies. Kidney cancer patients with regional lymph node metastasis have a slight but significant increase in the risk of overall death and cancer‐specific death compared to those without regional lymph node metastasis, therefore regional lymph node metastasis may be an indicator for radical nephrectomy surgery. Because of the limitation of the present study, larger and prospective studies are needed to validate our findings.
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